Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies

The Annals of Pharmacotherapy
A Brett HauberSemra Ozdemir

Abstract

Idiopathic thrombocytopenic purpura (ITP) primarily is a disorder of adults characterized by autoantibody-induced platelet destruction and reduced platelet production, leading to a low peripheral blood platelet count. The long-term management of many patients with chronic ITP is unsatisfactory, largely due to the variable efficacy and risks of severe adverse effects associated with current treatment options. To estimate patients' benefit-risk preferences for treatments for ITP. Patients' adverse event risk tolerance and the levels of benefit required to offset possible risks were evaluated using choice-format conjoint analysis. Subjects chose between pairs of hypothetical treatment alternatives defined by probability of achieving safe platelet levels, need for corticosteroids, mode of administration, risk of rebound, risk of elevated liver enzyme levels, and risk of thromboembolism. In this study, we demonstrate that patients have clear and measurable benefit-risk preferences that physicians should consider when discussing treatment options with their patients. Patients were willing to accept significant risks of adverse events in return for an increase in the probability of achieving safe platelet levels, to avoid corticostero...Continue Reading

References

Jul 1, 1986·American Journal of Hematology·A SalamaC Mueller-Eckhardt
Feb 15, 1997·Annals of Internal Medicine·R McMillan
Jun 2, 2000·BMJ : British Medical Journal·M Ryan, S Farrar
Jun 16, 2000·Journal of the National Cancer Institute. Monographs·I M Lipkus, J G Hollands
Mar 29, 2002·The New England Journal of Medicine·Douglas B Cines, Victor S Blanchette
Aug 30, 2002·British Journal of Haematology·Drew Provan, Adrian Newland
Feb 18, 2003·British Journal of Haematology·UNKNOWN British Committee for Standards in Haematology General Haematology Task Force
Dec 12, 2003·Journal of Pediatric Hematology/oncology·Drew Provan, Adrian Newland
Apr 7, 2004·Mayo Clinic Proceedings·James N George, Sara K Vesely
Apr 7, 2004·Mayo Clinic Proceedings·Roberto Stasi, Drew Provan
Jun 9, 2005·Blood·Douglas B Cines, James B Bussel
Jan 4, 2007·Annals of Internal Medicine·Donald M ArnoldJohn G Kelton
Oct 2, 2007·Journal of Women's Health·F Reed JohnsonTeresa L Kauf
Jan 29, 2008·Journal of Thrombosis and Haemostasis : JTH·M A Feudjo-TepieD Bennett
Feb 18, 2009·Annals of Internal Medicine·Lisa M SchwartzH Gilbert Welch
Feb 26, 2009·Annals of Internal Medicine·Jerry Avorn, William H Shrank

❮ Previous
Next ❯

Citations

May 3, 2013·Applied Health Economics and Health Policy·A Brett HauberF Reed Johnson
Aug 15, 2013·Pain Practice : the Official Journal of World Institute of Pain·Robert Andrew MoorePaul Emery
Feb 12, 2011·Medical Decision Making : an International Journal of the Society for Medical Decision Making·George Van HoutvenA Brett Hauber
Feb 15, 2012·European Journal of Gastroenterology & Hepatology·Ateesha Farah MohamedAllan Masterson
Dec 12, 2012·Journal of Occupational and Environmental Medicine·Janet SchwartzThomas Emerick
Dec 29, 2020·Hand : Official Journal of the American Association for Hand Surgery·Amirreza FatehiGregg A Vagner

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.